Impact of in vitro experimental variation in kinetic parameters on physiologically based kinetic (PBK) model simulations.
暂无分享,去创建一个
J. Louisse | A. Punt | B. Hakkert | P. Bos
[1] E. Fabian,et al. Predictive Performance of Next Generation Human Physiologically Based Kinetic (PBK) Models Based on In Vitro and In Silico Input Data , 2022 .
[2] Juan Manuel Parra Morte,et al. Scientific Opinion of the Scientific Panel on Plant Protection Products and their Residues (PPR Panel) on testing and interpretation of comparative in vitro metabolism studies , 2021, EFSA journal. European Food Safety Authority.
[3] T. Vanhaecke,et al. The SCCS Notes of Guidance for the Testing of Cosmetic Ingredients and their Safety Evaluation 11th revision, 30-31 March 2021, SCCS/1628/21. , 2021, Regulatory toxicology and pharmacology : RTP.
[4] E. Mendoza-de Gyves,et al. Determination of in vitro metabolic hepatic clearance of valproic acid (VPA) and five analogues by UPLC-MS-QTOF, applicable in alternatives to animal testing. , 2021, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[5] S. Hellberg,et al. Comparison between lab variability and in silico prediction errors for the unbound fraction of drugs in human plasma , 2021, Xenobiotica; the fate of foreign compounds in biological systems.
[6] T. Vanhaecke,et al. An overview of current practices for regulatory risk assessment with lessons learnt from cosmetics in the European Union , 2021, Critical reviews in toxicology.
[7] J. Dorne,et al. Derivation of a Human In Vivo Benchmark Dose for Perfluorooctanoic Acid From ToxCast In Vitro Concentration–Response Data Using a Computational Workflow for Probabilistic Quantitative In Vitro to In Vivo Extrapolation , 2021, Frontiers in Pharmacology.
[8] J. Nichols,et al. Evaluation and comparison of in vitro intrinsic clearance rates measured using cryopreserved hepatocytes from humans, rats, and rainbow trout. , 2021, Toxicology.
[9] Y. Tan,et al. Gaining acceptance in next generation PBK modelling approaches for regulatory assessments – An OECD international effort , 2021, Computational toxicology.
[10] E. Benfenati,et al. Towards a systematic use of effect biomarkers in population and occupational biomonitoring. , 2021, Environment international.
[11] H. Shalan,et al. Assessment of Cytochrome P450 Metabolic Clearance Using Hepatocyte Suspension , 2021, Methods in Pharmacology and Toxicology.
[12] Sangwoo Ryu,et al. Determination of Fraction Unbound and Unbound Partition Coefficient to Estimate Intracellular Free Drug Concentration , 2021 .
[13] Guidance document on the characterisation, validation and reporting of Physiologically Based Kinetic (PBK) models for regulatory purposes , 2021, OECD Series on Testing and Assessment.
[14] A. Peijnenburg,et al. Development of a Web-Based Toolbox to Support Quantitative In-Vitro-to-In-Vivo Extrapolations (QIVIVE) within Nonanimal Testing Strategies , 2020, Chemical research in toxicology.
[15] A. Srivastava,et al. A novel method for preventing non-specific binding in equilibrium dialysis assays using Solutol® as an additive. , 2020, Journal of pharmaceutical sciences.
[16] S. Ohkawara,et al. In vitro glucuronidation of bisphenol A in liver and intestinal microsomes: interspecies differences in humans and laboratory animals , 2020, Drug and chemical toxicology.
[17] B. van de Water,et al. Animal-free strategies in food safety & nutrition: What are we waiting for? Part I: Food safety , 2020 .
[18] Jae H. Chang,et al. Evaluation of a competitive equilibrium dialysis approach for assessing the impact of protein binding on clearance predictions. , 2020, Journal of pharmaceutical sciences.
[19] Bas J Blaauboer,et al. New approach methodologies (NAMs) for human-relevant biokinetics predictions: Meeting the paradigm shift in toxicology towards an animal-free chemical risk assessment. , 2020, ALTEX.
[20] Sandra Coecke,et al. Towards harmonization of test methods for in vitro hepatic clearance studies. , 2019, Toxicology in vitro : an international journal published in association with BIBRA.
[21] Robert G. Pearce,et al. Assessing Toxicokinetic Uncertainty and Variability in Risk Prioritization. , 2019, Toxicological sciences : an official journal of the Society of Toxicology.
[22] Ann M Richard,et al. Utility of In Vitro Bioactivity as a Lower Bound Estimate of In Vivo Adverse Effect Levels and in Risk-Based Prioritization. , 2019, Toxicological sciences : an official journal of the Society of Toxicology.
[23] I. Rusyn,et al. Comparative analysis of Rapid Equilibrium Dialysis (RED) and solid phase micro-extraction (SPME) methods for In Vitro-In Vivo extrapolation of environmental chemicals. , 2019, Toxicology in vitro : an international journal published in association with BIBRA.
[24] Hea‐Young Cho,et al. Interpretation of Non-Clinical Data for Prediction of Human Pharmacokinetic Parameters: In Vitro-In Vivo Extrapolation and Allometric Scaling , 2019, Pharmaceutics.
[25] Zhengyin Yan,et al. Improving Confidence in the Determination of Free Fraction for Highly Bound Drugs Using Bidirectional Equilibrium Dialysis. , 2019, Journal of pharmaceutical sciences.
[26] P. Magni,et al. Building in-house PBPK modelling tools for oral drug administration from literature information , 2019, ADMET & DMPK.
[27] Harvey J Clewell,et al. Developing context appropriate toxicity testing approaches using new alternative methods (NAMs). , 2019, ALTEX.
[28] Andrew Worth,et al. Establishing a systematic framework to characterise in vitro methods for human hepatic metabolic clearance. , 2018, Toxicology in vitro : an international journal published in association with BIBRA.
[29] Kenji Mizuguchi,et al. Predicting Fraction Unbound in Human Plasma from Chemical Structure: Improved Accuracy in the Low Value Ranges. , 2018, Molecular pharmaceutics.
[30] T. Puzyn,et al. Implementation of a dynamic intestinal gut-on-a-chip barrier model for transport studies of lipophilic dioxin congeners , 2018, RSC advances.
[31] George Loizou,et al. A Computational Workflow for Probabilistic Quantitative in Vitro to in Vivo Extrapolation , 2018, Front. Pharmacol..
[32] H. Segner,et al. Reliability of In Vitro Methods Used to Measure Intrinsic Clearance of Hydrophobic Organic Chemicals by Rainbow Trout: Results of an International Ring Trial , 2018, Toxicological sciences : an official journal of the Society of Toxicology.
[33] Min Gi Kim,et al. Quantitative analysis of lab‐to‐lab variability in Caco‐2 permeability assays , 2017, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[34] Ans Punt,et al. Non-animal approaches for toxicokinetics in risk evaluations of food chemicals. , 2017, ALTEX.
[35] Jochem Louisse,et al. Use of Physiologically Based Kinetic Modeling-Based Reverse Dosimetry to Predict in Vivo Toxicity from in Vitro Data. , 2017, Chemical research in toxicology.
[36] K. Korzekwa,et al. A physiologically based pharmacokinetic model to predict the pharmacokinetics of highly protein‐bound drugs and the impact of errors in plasma protein binding , 2016, Biopharmaceutics & drug disposition.
[37] Jingjing Yu,et al. Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model Verification , 2015, Drug Metabolism and Disposition.
[38] Sandra Coecke,et al. Biotransformation in vitro: An essential consideration in the quantitative in vitro-to-in vivo extrapolation (QIVIVE) of toxicity data. , 2015, Toxicology.
[39] L. Benet,et al. The utility of in vitro trials that use Caco-2 cell systems as a replacement for animal intestinal permeability and human bioequivalence measurements in drug development , 2015 .
[40] Bernard K. Choi,et al. Understanding and reducing the experimental variability of in vitro plasma protein binding measurements. , 2014, Journal of pharmaceutical sciences.
[41] L. Benet,et al. Distinguishing between the Permeability Relationships with Absorption and Metabolism To Improve BCS and BDDCS Predictions in Early Drug Discovery , 2014, Molecular pharmaceutics.
[42] Harvey J Clewell,et al. PBTK modelling platforms and parameter estimation tools to enable animal-free risk assessment: recommendations from a joint EPAA--EURL ECVAM ADME workshop. , 2014, Regulatory toxicology and pharmacology : RTP.
[43] B. Blaauboer. In Vitro Approaches to Predictive Biokinetics , 2014 .
[44] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[45] E. Seibert,et al. Fundamentals of enzyme kinetics. , 2014, Methods in molecular biology.
[46] George Loizou,et al. Toxicokinetics as a key to the integrated toxicity risk assessment based primarily on non-animal approaches. , 2013, Toxicology in vitro : an international journal published in association with BIBRA.
[47] K Rowland-Yeo,et al. Basic Concepts in Physiologically Based Pharmacokinetic Modeling in Drug Discovery and Development , 2013, CPT: pharmacometrics & systems pharmacology.
[48] Erik Sjögren,et al. Optimized Experimental Design for the Estimation of Enzyme Kinetic Parameters: An Experimental Evaluation , 2012, Drug Metabolism and Disposition.
[49] J. Houston,et al. Clearance-dependent underprediction of in vivo intrinsic clearance from human hepatocytes: comparison with permeabilities from artificial membrane (PAMPA) assay, in silico and caco-2 assay, for 65 drugs. , 2012, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[50] A. Harsch,et al. Direct determination of the ratio of unbound fraction in plasma to unbound fraction in microsomal system (fu p/fu mic) for refined prediction of phase I mediated metabolic hepatic clearance. , 2011, Journal of pharmacological and toxicological methods.
[51] J. Lipscomb,et al. Differences between Human and Rat Intestinal and Hepatic Bisphenol A Glucuronidation and the Influence of Alamethicin on In Vitro Kinetic Measurements , 2010, Drug Metabolism and Disposition.
[52] Michael Gertz,et al. Prediction of Human Intestinal First-Pass Metabolism of 25 CYP3A Substrates from In Vitro Clearance and Permeability Data , 2010, Drug Metabolism and Disposition.
[53] John C Lipscomb,et al. In vitro measurements of metabolism for application in pharmacokinetic modeling. , 2008, Pharmacology & therapeutics.
[54] Walter Schmitt,et al. General approach for the calculation of tissue to plasma partition coefficients. , 2008, Toxicology in vitro : an international journal published in association with BIBRA.
[56] Tongtong Liu,et al. Development of In Vitro Pharmacokinetic Screens Using Caco-2, Human Hepatocyte, and Caco-2/Human Hepatocyte Hybrid Systems for the Prediction of Oral Bioavailability in Humans , 2007, Journal of biomolecular screening.
[57] O. Pelkonen,et al. In vitro–in vivo extrapolation of hepatic clearance: Biological tools, scaling factors, model assumptions and correct concentrations , 2007, Xenobiotica; the fate of foreign compounds in biological systems.
[58] P. Artursson,et al. Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers , 2007, Nature Protocols.
[59] M. Rowland,et al. Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. , 2006, Journal of pharmaceutical sciences.
[60] P. Sinko,et al. Estimating Human Drug Oral Absorption Kinetics from Caco-2 Permeability Using an Absorption-Disposition Model: Model Development and Evaluation and Derivation of Analytical Solutions for ka and Fa , 2005, Journal of Pharmacology and Experimental Therapeutics.
[61] Hannah M Jones,et al. SUBSTRATE DEPLETION APPROACH FOR DETERMINING IN VITRO METABOLIC CLEARANCE: TIME DEPENDENCIES IN HEPATOCYTE AND MICROSOMAL INCUBATIONS , 2004, Drug Metabolism and Disposition.
[62] Tingjun Hou,et al. ADME Evaluation in Drug Discovery. 5. Correlation of Caco-2 Permeation with Simple Molecular Properties , 2004, J. Chem. Inf. Model..
[63] L. Berezhkovskiy,et al. Volume of distribution at steady state for a linear pharmacokinetic system with peripheral elimination. , 2004, Journal of pharmaceutical sciences.
[64] Ismael Zamora,et al. pH-Dependent Bidirectional Transport of Weakly Basic Drugs Across Caco-2 Monolayers: Implications for Drug–Drug Interactions , 2003, Pharmaceutical Research.
[65] Tingjun Hou,et al. ADME evaluation in drug discovery , 2002, Journal of molecular modeling.
[66] J. Ashby,et al. Comparison of the modulatory effects of human and rat liver microsomal metabolism on the estrogenicity of bisphenol A: implications for extrapolation to humans. , 2001, The Journal of pharmacology and experimental therapeutics.
[67] E D Schoen,et al. Assessment of some critical factors in the freezing technique for the cryopreservation of precision-cut rat liver slices. , 2000, Cryobiology.
[68] G L Amidon,et al. A compartmental absorption and transit model for estimating oral drug absorption. , 1999, International journal of pharmaceutics.